Loading…
Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers
Abstract Context Despite its good prognosis, differentiated thyroid cancer (DTC) is characterized by high rates of disease persistence and recurrence. Estimation of long-term remission (excellent response) thanks to specific parameters could help to individualize the active surveillance schedule. Ob...
Saved in:
| Published in: | The journal of clinical endocrinology and metabolism 2019-08, Vol.104 (8), p.3462-3472 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5360-5c896ef5069421d4b5f28b71e1ffae76a12fd0b3c38a79caf1cc3bbe1d1b0d533 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5360-5c896ef5069421d4b5f28b71e1ffae76a12fd0b3c38a79caf1cc3bbe1d1b0d533 |
| container_end_page | 3472 |
| container_issue | 8 |
| container_start_page | 3462 |
| container_title | The journal of clinical endocrinology and metabolism |
| container_volume | 104 |
| creator | Barres, Bertrand Kelly, Antony Kwiatkowski, Fabrice Batisse-Lignier, Marie Fouilhoux, Geneviève Aubert, Bernadette Dutheil, Frédéric Tauveron, Igor Cachin, Florent Maqdasy, Salwan |
| description | Abstract
Context
Despite its good prognosis, differentiated thyroid cancer (DTC) is characterized by high rates of disease persistence and recurrence. Estimation of long-term remission (excellent response) thanks to specific parameters could help to individualize the active surveillance schedule.
Objective
Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation.
Patients and Interventions
Observational retrospective study of 1093 patients treated for DTC between 1995 and 2010. Preablation stimulated thyroglobulin (presTg) was measured under thyroid hormone withdrawal just before RAI. Recombinant human TSH–stimulated thyroglobulin (sTg) was measured at first evaluation of the initial management 6 to 12 months after RAI. TRI was calculated based on pre-Tg and sTg.
Results
After univariate and multivariate analyses, lymph node invasion (N1, OR = 2.08; 95% CI, 1.19 to 3.64), presTg (OR = 4.04; 95% CI, 2.56 to 6.38), sTg (OR = 2.62; 95% CI, 2.05 to 3.34), and TRI (OR = 0.43; 95% CI, 0.21 to 0.88) were identified as independent prognostic factors influencing the rate of disease persistence or recurrence after the initial management. Receiver operating characteristic analysis identified presTg cutoff ( |
| doi_str_mv | 10.1210/jc.2018-02680 |
| format | article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02975494v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A688567571</galeid><oup_id>10.1210/jc.2018-02680</oup_id><sourcerecordid>A688567571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5360-5c896ef5069421d4b5f28b71e1ffae76a12fd0b3c38a79caf1cc3bbe1d1b0d533</originalsourceid><addsrcrecordid>eNp1ksFv0zAYxSMEYt3gyBVF4gKHFNuJ7eRYlcEmVQLBkLhZjv15dXHsYid0---X0G4TFcgHS0-_79nPfln2CqM5Jhi936g5QbguEGE1epLNcFPRguOGP81mCBFcNJz8OMlOU9oghKuKls-zkxLxmjYNnWW7b73tBid70PnV-jaGaxfawVmfS3-sfAU9qN4Gn196DTf5lwjaqj4_v1HgHPh-JNI2-AT5SH-wxkAcVftobnW-lF5BTC-yZ0a6BC8P-1n2_eP51fKiWH3-dLlcrApFS4YKquqGgaGINRXBumqpIXXLMWBjJHAmMTEataUqa8kbJQ1WqmxbwBq3SNOyPMve7X3X0olttJ2MtyJIKy4WKzFpiDScVk31G4_s2z27jeHXAKkXnU1TNOkhDEkQXFeUcEon9M0RuglD9GMSQUpWEVYSRh-pa-lAWG9CH6WaTMWC1TVlnPLJa_4PalwaOquCB2NH_a-BYj-gYkgpgnkIhpGYSiE2SkylEH9KMfKvD5cd2g70A33fghHAe2AXXD9-zk837CCKNUjXr49Ni3vTw2OFYfu_8w_oHYelzYw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2364263265</pqid></control><display><type>article</type><title>Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers</title><source>Oxford Journals Online</source><creator>Barres, Bertrand ; Kelly, Antony ; Kwiatkowski, Fabrice ; Batisse-Lignier, Marie ; Fouilhoux, Geneviève ; Aubert, Bernadette ; Dutheil, Frédéric ; Tauveron, Igor ; Cachin, Florent ; Maqdasy, Salwan</creator><creatorcontrib>Barres, Bertrand ; Kelly, Antony ; Kwiatkowski, Fabrice ; Batisse-Lignier, Marie ; Fouilhoux, Geneviève ; Aubert, Bernadette ; Dutheil, Frédéric ; Tauveron, Igor ; Cachin, Florent ; Maqdasy, Salwan</creatorcontrib><description>Abstract
Context
Despite its good prognosis, differentiated thyroid cancer (DTC) is characterized by high rates of disease persistence and recurrence. Estimation of long-term remission (excellent response) thanks to specific parameters could help to individualize the active surveillance schedule.
Objective
Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation.
Patients and Interventions
Observational retrospective study of 1093 patients treated for DTC between 1995 and 2010. Preablation stimulated thyroglobulin (presTg) was measured under thyroid hormone withdrawal just before RAI. Recombinant human TSH–stimulated thyroglobulin (sTg) was measured at first evaluation of the initial management 6 to 12 months after RAI. TRI was calculated based on pre-Tg and sTg.
Results
After univariate and multivariate analyses, lymph node invasion (N1, OR = 2.08; 95% CI, 1.19 to 3.64), presTg (OR = 4.04; 95% CI, 2.56 to 6.38), sTg (OR = 2.62; 95% CI, 2.05 to 3.34), and TRI (OR = 0.43; 95% CI, 0.21 to 0.88) were identified as independent prognostic factors influencing the rate of disease persistence or recurrence after the initial management. Receiver operating characteristic analysis identified presTg cutoff (<10 µg/L) to predict excellent response, with a negative predictive value of 94%, and validated for higher stages (T3/T4, N1). Furthermore, sTg <1 µg/L predicts excellent response. TRI >60% for the entire cohort and 62.5% for locally advanced disease (T3/T4, N1) was sensitive predictor for excellent response.
Conclusion
This study identifies presTg, sTg, and TRI as highly sensitive predictors of excellent response in patients with DTC and subsequently disease-free status. The cutoff of such parameters is also adapted for patients with higher tumor stages (T3/T4, N1).
presTg (<10 µg/L) and TRI (<60%) predict excellent response in patients with DTC managed by thyroidectomy and RAI remnant ablation.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2018-02680</identifier><identifier>PMID: 30785995</identifier><language>eng</language><publisher>Washington, DC: Endocrine Society</publisher><subject>Adult ; Antineoplastic Protocols ; Cancer ; Combined Modality Therapy ; Diseases ; Female ; Humans ; Iodine ; Iodine Radioisotopes ; Life Sciences ; Lymph nodes ; Male ; Medical prognosis ; Medical research ; Medicine, Experimental ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Radiofrequency Ablation ; Relapse ; Remission ; Remission Induction ; Retrospective Studies ; Thyroglobulin ; Thyroglobulin - blood ; Thyroid cancer ; Thyroid gland ; Thyroid Hormones - blood ; Thyroid Neoplasms - blood ; Thyroid Neoplasms - therapy ; Thyroid-stimulating hormone ; Thyroidectomy ; Thyroxine ; Treatment Outcome ; Triiodothyronine</subject><ispartof>The journal of clinical endocrinology and metabolism, 2019-08, Vol.104 (8), p.3462-3472</ispartof><rights>Copyright © 2019 Endocrine Society 2019</rights><rights>Copyright © Oxford University Press 2015</rights><rights>Copyright © 2019 Endocrine Society.</rights><rights>COPYRIGHT 2019 Oxford University Press</rights><rights>Copyright © 2019 Endocrine Society</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5360-5c896ef5069421d4b5f28b71e1ffae76a12fd0b3c38a79caf1cc3bbe1d1b0d533</citedby><cites>FETCH-LOGICAL-c5360-5c896ef5069421d4b5f28b71e1ffae76a12fd0b3c38a79caf1cc3bbe1d1b0d533</cites><orcidid>0000-0001-5164-9879 ; 0000-0002-1468-6029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30785995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02975494$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Barres, Bertrand</creatorcontrib><creatorcontrib>Kelly, Antony</creatorcontrib><creatorcontrib>Kwiatkowski, Fabrice</creatorcontrib><creatorcontrib>Batisse-Lignier, Marie</creatorcontrib><creatorcontrib>Fouilhoux, Geneviève</creatorcontrib><creatorcontrib>Aubert, Bernadette</creatorcontrib><creatorcontrib>Dutheil, Frédéric</creatorcontrib><creatorcontrib>Tauveron, Igor</creatorcontrib><creatorcontrib>Cachin, Florent</creatorcontrib><creatorcontrib>Maqdasy, Salwan</creatorcontrib><title>Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Abstract
Context
Despite its good prognosis, differentiated thyroid cancer (DTC) is characterized by high rates of disease persistence and recurrence. Estimation of long-term remission (excellent response) thanks to specific parameters could help to individualize the active surveillance schedule.
Objective
Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation.
Patients and Interventions
Observational retrospective study of 1093 patients treated for DTC between 1995 and 2010. Preablation stimulated thyroglobulin (presTg) was measured under thyroid hormone withdrawal just before RAI. Recombinant human TSH–stimulated thyroglobulin (sTg) was measured at first evaluation of the initial management 6 to 12 months after RAI. TRI was calculated based on pre-Tg and sTg.
Results
After univariate and multivariate analyses, lymph node invasion (N1, OR = 2.08; 95% CI, 1.19 to 3.64), presTg (OR = 4.04; 95% CI, 2.56 to 6.38), sTg (OR = 2.62; 95% CI, 2.05 to 3.34), and TRI (OR = 0.43; 95% CI, 0.21 to 0.88) were identified as independent prognostic factors influencing the rate of disease persistence or recurrence after the initial management. Receiver operating characteristic analysis identified presTg cutoff (<10 µg/L) to predict excellent response, with a negative predictive value of 94%, and validated for higher stages (T3/T4, N1). Furthermore, sTg <1 µg/L predicts excellent response. TRI >60% for the entire cohort and 62.5% for locally advanced disease (T3/T4, N1) was sensitive predictor for excellent response.
Conclusion
This study identifies presTg, sTg, and TRI as highly sensitive predictors of excellent response in patients with DTC and subsequently disease-free status. The cutoff of such parameters is also adapted for patients with higher tumor stages (T3/T4, N1).
presTg (<10 µg/L) and TRI (<60%) predict excellent response in patients with DTC managed by thyroidectomy and RAI remnant ablation.</description><subject>Adult</subject><subject>Antineoplastic Protocols</subject><subject>Cancer</subject><subject>Combined Modality Therapy</subject><subject>Diseases</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine</subject><subject>Iodine Radioisotopes</subject><subject>Life Sciences</subject><subject>Lymph nodes</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Radiofrequency Ablation</subject><subject>Relapse</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Thyroglobulin</subject><subject>Thyroglobulin - blood</subject><subject>Thyroid cancer</subject><subject>Thyroid gland</subject><subject>Thyroid Hormones - blood</subject><subject>Thyroid Neoplasms - blood</subject><subject>Thyroid Neoplasms - therapy</subject><subject>Thyroid-stimulating hormone</subject><subject>Thyroidectomy</subject><subject>Thyroxine</subject><subject>Treatment Outcome</subject><subject>Triiodothyronine</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1ksFv0zAYxSMEYt3gyBVF4gKHFNuJ7eRYlcEmVQLBkLhZjv15dXHsYid0---X0G4TFcgHS0-_79nPfln2CqM5Jhi936g5QbguEGE1epLNcFPRguOGP81mCBFcNJz8OMlOU9oghKuKls-zkxLxmjYNnWW7b73tBid70PnV-jaGaxfawVmfS3-sfAU9qN4Gn196DTf5lwjaqj4_v1HgHPh-JNI2-AT5SH-wxkAcVftobnW-lF5BTC-yZ0a6BC8P-1n2_eP51fKiWH3-dLlcrApFS4YKquqGgaGINRXBumqpIXXLMWBjJHAmMTEataUqa8kbJQ1WqmxbwBq3SNOyPMve7X3X0olttJ2MtyJIKy4WKzFpiDScVk31G4_s2z27jeHXAKkXnU1TNOkhDEkQXFeUcEon9M0RuglD9GMSQUpWEVYSRh-pa-lAWG9CH6WaTMWC1TVlnPLJa_4PalwaOquCB2NH_a-BYj-gYkgpgnkIhpGYSiE2SkylEH9KMfKvD5cd2g70A33fghHAe2AXXD9-zk837CCKNUjXr49Ni3vTw2OFYfu_8w_oHYelzYw</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Barres, Bertrand</creator><creator>Kelly, Antony</creator><creator>Kwiatkowski, Fabrice</creator><creator>Batisse-Lignier, Marie</creator><creator>Fouilhoux, Geneviève</creator><creator>Aubert, Bernadette</creator><creator>Dutheil, Frédéric</creator><creator>Tauveron, Igor</creator><creator>Cachin, Florent</creator><creator>Maqdasy, Salwan</creator><general>Endocrine Society</general><general>Copyright Oxford University Press</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-5164-9879</orcidid><orcidid>https://orcid.org/0000-0002-1468-6029</orcidid></search><sort><creationdate>20190801</creationdate><title>Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers</title><author>Barres, Bertrand ; Kelly, Antony ; Kwiatkowski, Fabrice ; Batisse-Lignier, Marie ; Fouilhoux, Geneviève ; Aubert, Bernadette ; Dutheil, Frédéric ; Tauveron, Igor ; Cachin, Florent ; Maqdasy, Salwan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5360-5c896ef5069421d4b5f28b71e1ffae76a12fd0b3c38a79caf1cc3bbe1d1b0d533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Antineoplastic Protocols</topic><topic>Cancer</topic><topic>Combined Modality Therapy</topic><topic>Diseases</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine</topic><topic>Iodine Radioisotopes</topic><topic>Life Sciences</topic><topic>Lymph nodes</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Radiofrequency Ablation</topic><topic>Relapse</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Thyroglobulin</topic><topic>Thyroglobulin - blood</topic><topic>Thyroid cancer</topic><topic>Thyroid gland</topic><topic>Thyroid Hormones - blood</topic><topic>Thyroid Neoplasms - blood</topic><topic>Thyroid Neoplasms - therapy</topic><topic>Thyroid-stimulating hormone</topic><topic>Thyroidectomy</topic><topic>Thyroxine</topic><topic>Treatment Outcome</topic><topic>Triiodothyronine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barres, Bertrand</creatorcontrib><creatorcontrib>Kelly, Antony</creatorcontrib><creatorcontrib>Kwiatkowski, Fabrice</creatorcontrib><creatorcontrib>Batisse-Lignier, Marie</creatorcontrib><creatorcontrib>Fouilhoux, Geneviève</creatorcontrib><creatorcontrib>Aubert, Bernadette</creatorcontrib><creatorcontrib>Dutheil, Frédéric</creatorcontrib><creatorcontrib>Tauveron, Igor</creatorcontrib><creatorcontrib>Cachin, Florent</creatorcontrib><creatorcontrib>Maqdasy, Salwan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barres, Bertrand</au><au>Kelly, Antony</au><au>Kwiatkowski, Fabrice</au><au>Batisse-Lignier, Marie</au><au>Fouilhoux, Geneviève</au><au>Aubert, Bernadette</au><au>Dutheil, Frédéric</au><au>Tauveron, Igor</au><au>Cachin, Florent</au><au>Maqdasy, Salwan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>104</volume><issue>8</issue><spage>3462</spage><epage>3472</epage><pages>3462-3472</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Abstract
Context
Despite its good prognosis, differentiated thyroid cancer (DTC) is characterized by high rates of disease persistence and recurrence. Estimation of long-term remission (excellent response) thanks to specific parameters could help to individualize the active surveillance schedule.
Objective
Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation.
Patients and Interventions
Observational retrospective study of 1093 patients treated for DTC between 1995 and 2010. Preablation stimulated thyroglobulin (presTg) was measured under thyroid hormone withdrawal just before RAI. Recombinant human TSH–stimulated thyroglobulin (sTg) was measured at first evaluation of the initial management 6 to 12 months after RAI. TRI was calculated based on pre-Tg and sTg.
Results
After univariate and multivariate analyses, lymph node invasion (N1, OR = 2.08; 95% CI, 1.19 to 3.64), presTg (OR = 4.04; 95% CI, 2.56 to 6.38), sTg (OR = 2.62; 95% CI, 2.05 to 3.34), and TRI (OR = 0.43; 95% CI, 0.21 to 0.88) were identified as independent prognostic factors influencing the rate of disease persistence or recurrence after the initial management. Receiver operating characteristic analysis identified presTg cutoff (<10 µg/L) to predict excellent response, with a negative predictive value of 94%, and validated for higher stages (T3/T4, N1). Furthermore, sTg <1 µg/L predicts excellent response. TRI >60% for the entire cohort and 62.5% for locally advanced disease (T3/T4, N1) was sensitive predictor for excellent response.
Conclusion
This study identifies presTg, sTg, and TRI as highly sensitive predictors of excellent response in patients with DTC and subsequently disease-free status. The cutoff of such parameters is also adapted for patients with higher tumor stages (T3/T4, N1).
presTg (<10 µg/L) and TRI (<60%) predict excellent response in patients with DTC managed by thyroidectomy and RAI remnant ablation.</abstract><cop>Washington, DC</cop><pub>Endocrine Society</pub><pmid>30785995</pmid><doi>10.1210/jc.2018-02680</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-5164-9879</orcidid><orcidid>https://orcid.org/0000-0002-1468-6029</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-972X |
| ispartof | The journal of clinical endocrinology and metabolism, 2019-08, Vol.104 (8), p.3462-3472 |
| issn | 0021-972X 1945-7197 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02975494v1 |
| source | Oxford Journals Online |
| subjects | Adult Antineoplastic Protocols Cancer Combined Modality Therapy Diseases Female Humans Iodine Iodine Radioisotopes Life Sciences Lymph nodes Male Medical prognosis Medical research Medicine, Experimental Middle Aged Predictive Value of Tests Prognosis Radiofrequency Ablation Relapse Remission Remission Induction Retrospective Studies Thyroglobulin Thyroglobulin - blood Thyroid cancer Thyroid gland Thyroid Hormones - blood Thyroid Neoplasms - blood Thyroid Neoplasms - therapy Thyroid-stimulating hormone Thyroidectomy Thyroxine Treatment Outcome Triiodothyronine |
| title | Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A58%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stimulated%20Thyroglobulin%20and%20Thyroglobulin%20Reduction%20Index%20Predict%20Excellent%20Response%20in%20Differentiated%20Thyroid%20Cancers&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Barres,%20Bertrand&rft.date=2019-08-01&rft.volume=104&rft.issue=8&rft.spage=3462&rft.epage=3472&rft.pages=3462-3472&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/jc.2018-02680&rft_dat=%3Cgale_hal_p%3EA688567571%3C/gale_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5360-5c896ef5069421d4b5f28b71e1ffae76a12fd0b3c38a79caf1cc3bbe1d1b0d533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2364263265&rft_id=info:pmid/30785995&rft_galeid=A688567571&rft_oup_id=10.1210/jc.2018-02680&rfr_iscdi=true |